Jim Cramer, host of Mad Money, recently discussed the current state of the market and also discussed both the leading and ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...